Skip to main content
News Icon

Publication

Study for treatment of lymphatic filariosis in Science Translational Medicine published

Neglected tropical diseases such as Lymphatic filariosis are common in tropical and subtropical areas. Here mostly poor people are affected.
An international consortium with a contribution of scientists from the Cluster of Excellence ImmunoSensation identified a new substance ABBV-4083 in the fight against adult worms, the cause of lymphatic filariosis.
Dr. Marc Hübner and Prof. Hörauf are working in the Institute of Medical Microbiology, Immunology and Parasitology at the University Hospital Bonn.


Publication

Mark J. Taylor, Thomas W. von Geldern, Louise Ford, Marc P. Hübner, Kennan Marsh, Kelly L. Johnston, Hanna T. Sjoberg, Sabine Specht, Nicolas Pionnier, Hayley E. Tyrer, Rachel H. Clare, Darren A. N. Cook, Emma Murphy, Andrew Steven, John Archer, Dominique Bloemker, Franziska Lenz, Marianne Koschel, Alexandra Ehrens, Haelly M. Metuge, Valerinne C. Chunda, Patrick W. Ndongmo Chounna, Abdel J. Njouendou, Fanny F. Fombad, Robert Carr, Howard E. Morton, Ghaith Aljayyoussi, Achim Hoerauf, Samuel Wanji, Dale J. Kempf, Joseph D. Turner, Stephen A. Ward: Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis, Science Translational Medicine, DOI: 10.1126/scitranslmed.aau2086

Related news

Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

—As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

Publication

A Ray of Hope in the Fight Against Cancer

—Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry
(from left) Julia Nicke and Dr. Mona Malek Mohammadi have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury.

Publication

Central Hub for Heart Repair Discovered Bonn study: Heart muscle interaction enables cardiac regeneration in the neonatal heart

—Researchers at the University Hospital of Bonn (UKB) and the University of Bonn have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury. The findings could open new avenues for future therapies aimed at repairing damaged adult hearts after heart attacks or chronic cardiovascular disease. The study has now been published in the journal Cell Communication and Signaling (Springer Nature).
View entry

Back to the news overview